Jason Baum

838 total citations
30 papers, 656 citations indexed

About

Jason Baum is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jason Baum has authored 30 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Molecular Biology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jason Baum's work include Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Jason Baum is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), HER2/EGFR in Cancer Research (5 papers) and Gastric Cancer Management and Outcomes (5 papers). Jason Baum collaborates with scholars based in United States, China and South Korea. Jason Baum's co-authors include Kimberly McCall, Eli Arama, Hermann Steller, Jeanne S. Peterson, Alexey A. Lugovskoy, Ulrik B. Nielsen, Birgit Schoeberl, Victoria Rimkunas, Sharlene Adams and Sergio Iadevaia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Jason Baum

30 papers receiving 651 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Baum United States	11	348	258	141	110	103	30	656
Rodrigo Fernandez‐Valdivia United States	16	562 1.6×	245 0.9×	320 2.3×	72 0.7×	28 0.3×	25	1.1k
Christina Chaivorapol United States	8	503 1.4×	165 0.6×	288 2.0×	140 1.3×	33 0.3×	11	1.0k
Daechan Park South Korea	17	602 1.7×	152 0.6×	246 1.7×	118 1.1×	122 1.2×	33	979
Justine Guégan France	12	353 1.0×	71 0.3×	71 0.5×	141 1.3×	30 0.3×	23	627
Cristian Soza‐Ried Germany	12	262 0.8×	116 0.4×	160 1.1×	80 0.7×	83 0.8×	27	582
Arno Scheller United States	17	379 1.1×	289 1.1×	61 0.4×	121 1.1×	97 0.9×	18	820
Elisabeth Martin France	20	409 1.2×	160 0.6×	57 0.4×	26 0.2×	18 0.2×	36	791
Jan P. Gerlach Netherlands	10	864 2.5×	150 0.6×	82 0.6×	43 0.4×	34 0.3×	12	1.1k
Rob Burgess United States	8	544 1.6×	192 0.7×	178 1.3×	29 0.3×	25 0.2×	10	807
Hans Rotheneder Austria	15	1.1k 3.0×	469 1.8×	106 0.8×	41 0.4×	21 0.2×	18	1.3k

Countries citing papers authored by Jason Baum

Since Specialization

Citations

This map shows the geographic impact of Jason Baum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Baum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Baum more than expected).

Fields of papers citing papers by Jason Baum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Baum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Baum. The network helps show where Jason Baum may publish in the future.

Co-authorship network of co-authors of Jason Baum

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Baum. A scholar is included among the top collaborators of Jason Baum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Baum. Jason Baum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klempner, Samuel J., Mohamad Bassam Sonbol, Zev A. Wainberg, et al.. (2024). DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish. Journal of Clinical Oncology. 43(3). 339–349. 12 indexed citations

Klempner, Samuel J., Jaffer A. Ajani, Joseph Chao, et al.. (2022). 553 DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial. Regular and Young Investigator Award Abstracts. A578–A578. 1 indexed citations

Caldwell, Charles C., James B. Rottman, Vitria Adisetiyo, et al.. (2021). Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors. Scientific Reports. 11(1). 9920–9920. 11 indexed citations

Wong, Connie, Jason Baum, Michael T. Beste, et al.. (2020). Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial. Cancer Research. 80(24). 5597–5605. 63 indexed citations

Garon, Edward B., Andrea Ardizzoni, Fabrice Barlési, et al.. (2019). P2.01-02 CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC. Journal of Thoracic Oncology. 14(10). S638–S639. 1 indexed citations

Felip, Enriqueta, Filippo de Braud, Michela Maur, et al.. (2019). Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. Journal of Thoracic Oncology. 15(3). 392–403. 60 indexed citations

Jayaraman, Pushpa, John M. Millholland, Neil A. O’Brien, et al.. (2019). Abstract C103: Targeting IL-1β pathway for cancer immunotherapy. Molecular Cancer Therapeutics. 18(12_Supplement). C103–C103. 3 indexed citations

Pace, Emily A., Sharlene Adams, Michael D. Curley, et al.. (2018). Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clinical Cancer Research. 24(12). 2873–2885. 44 indexed citations

Ko, Andrew H., James H. Murray, Kerry Horgan, et al.. (2016). A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology. 34(4_suppl). TPS481–TPS481. 10 indexed citations

10.

Pace, Emily, Sharlene Adams, Michael Curley, et al.. (2015). Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation.. Journal of Clinical Oncology. 33(3_suppl). 289–289. 4 indexed citations

11.

Fitzgerald, Jonathan B., Bryan W. Johnson, Jason Baum, et al.. (2013). MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors. Molecular Cancer Therapeutics. 13(2). 410–425. 87 indexed citations

12.

Xu, Lihui, Neeraj Kohli, Rachel Rennard, et al.. (2013). Rapid optimization and prototyping for therapeutic antibody-like molecules. mAbs. 5(2). 237–254. 21 indexed citations

13.

Adams, Sharlene, Jason Baum, Victoria Rimkunas, et al.. (2013). Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer.. Molecular Cancer Therapeutics. 12(11_Supplement). C169–C169. 1 indexed citations

14.

Baum, Jason, Bryan W. Johnson, Sharlene Adams, et al.. (2012). Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity. Cancer Research. 72(8_Supplement). 2719–2719. 3 indexed citations

15.

Baum, Jason, Bryan W. Johnson, Sharlene Adams, et al.. (2012). 316 MM-141, a Novel Bispecific Antibody Co-targeting IGF-1R and ErbB3, Inhibits PI3K/Akt/mTOR Pro-survival Signaling in Preclinical Cancer Models. European Journal of Cancer. 48. 97–97. 2 indexed citations

16.

Lugovskoy, Alexey A., Bryan W. Johnson, Jason Baum, et al.. (2011). Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3.. Molecular Cancer Therapeutics. 10(11_Supplement). B205–B205. 2 indexed citations

17.

Baum, Jason, Eli Arama, Hermann Steller, & Kimberly McCall. (2007). The Drosophila caspases Strica and Dronc function redundantly in programmed cell death during oogenesis. Cell Death and Differentiation. 14(8). 1508–1517. 62 indexed citations

18.

Baum, Jason, et al.. (2005). Programmed cell death in the germline. Seminars in Cell and Developmental Biology. 16(2). 245–259. 111 indexed citations

19.

McCall, Kimberly, et al.. (2004). Visualizing Apoptosis. Humana Press eBooks. 247. 431–442. 7 indexed citations

20.

Peterson, Jeanne S., et al.. (2003). Germline Cell Death Is Inhibited by P-Element Insertions Disrupting the dcp-1/pita Nested Gene Pair in Drosophila. Genetics. 165(4). 1881–1888. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact